荣昌生物跌9.72% 华泰证券华安证券昨刚喊买入就跌

Core Viewpoint - Rongchang Biopharmaceutical (688331.SH) experienced a significant decline in stock price, closing at 103.34 yuan, down 9.72% [1] Group 1: Analyst Reports - Huatai Securities analysts Dai Wen, Yuan Zhongping, and Li Hang published a report on January 13, maintaining a WACC of 6.5% and a perpetual growth rate of 2.5%, adjusting the DCF-based target price for A-shares to 151.79 yuan (previously 140.42 yuan) [1] - The A/H premium was adjusted to 16.46%, consistent with the past three months' A/H premium for Rongchang Biopharmaceutical, up from the previous 8.95% [1] - The target price for H-shares was adjusted to 142.72 HKD (previously 141.13 HKD), with a "buy" rating maintained for both A-shares and H-shares [1] Group 2: Clinical Development and Product Pipeline - Huazhong Securities analysts Tan Guochao and Ren Wanying also published a report on January 13, expressing optimism about the clinical advancement of RC148, the progress of the company's pipeline, and the stable sales growth of its listed products, maintaining a "buy" rating [1]